ImmunoGen
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, ImmunoGen sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).
ImmunoGen: 15 sponsored US clinical trials, none currently recruiting.
ImmunoGen sponsors 15 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 13 completed. 2 of these trials are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-colorectal Cancer, with 1 trials.
Top-decile sponsor footprint
ImmunoGen ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
13 of 15 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
15 total, page 1 of 1
First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors
NCT04622774
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
NCT04296890
Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer
NCT02606305
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer
NCT02631876
Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia
NCT02674763
A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors
NCT01963715
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors
NCT01609556
IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
NCT01534715
A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer
NCT01237678
IMGN901 in Combination With Lenalidomide and Dexamethasone
NCT00991562
A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors
NCT00721669
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
NCT00346255
Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors
NCT00352131
Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer
NCT00065429
BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
NCT00346385
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 3 | 2 |
Therapeutic Areas
How the ImmunoGen early-phase archive is shaped
15 indexed studies, none listed as recruiting (0% open); 13 completed (87%).
Phase mix: 2 late (III/IV) vs 13 early (I/II) (early-phase heavy).
Top condition: Non-colorectal Cancer (1 trial), 7 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
ImmunoGen: archived-pipeline peers nationwide
Peers matched on 15 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
ImmunoGen sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 15 archived trials
- Allakos · 15 trials · 0% recruiting
- Arbor Research Collaborative for Health · 15 trials · 33% recruiting
- Arena Pharmaceuticals · 15 trials · 0% recruiting
- Arrowhead Pharmaceuticals · 15 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this ImmunoGen page
15 registered trials is a research-attention snapshot, not an endorsement of ImmunoGen or any single study.
- None of ImmunoGen's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Non-colorectal Cancer is the condition ImmunoGen studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-colorectal Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
ImmunoGen pipeline card: 15 registered trials from official public datasets.Report a data error.